1. Home
  2. CANF vs ARTL Comparison

CANF vs ARTL Comparison

Compare CANF & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.45

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.57

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
ARTL
Founded
1994
2011
Country
Israel
United States
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.3M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CANF
ARTL
Price
$3.45
$2.57
Analyst Decision
Buy
Hold
Analyst Count
2
2
Target Price
$50.00
N/A
AVG Volume (30 Days)
938.6K
431.8K
Earning Date
03-26-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2,715,455.50
N/A
Revenue Next Year
$101.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.90
52 Week High
$10.40
$28.60

Technical Indicators

Market Signals
Indicator
CANF
ARTL
Relative Strength Index (RSI) 56.46 33.86
Support Level $2.89 $1.62
Resistance Level $4.74 $3.67
Average True Range (ATR) 0.35 0.28
MACD 0.09 -0.16
Stochastic Oscillator 52.80 3.30

Price Performance

Historical Comparison
CANF
ARTL

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: